Kepos Capital’s MacroGenics MGNX Stock Holding History

Kepos Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-12,814	Closed	-$322K	–	349
2018 Q1	$322K	Buy	+12,814	New	+$311K	0.02%	242

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kepos Capital's MGNX Position: Q2 2018 in Review

Kepos Capital sold out of MacroGenics (MGNX) in Q2 2018, closing a stake of 12,814 shares — an estimated $322K sold.

Kepos Capital first reported a position in MGNX in Q1 2018 and held it in 1 quarter. The position peaked at $322K in Q1 2018. 127 funds tracked by Wall St. Rank hold MGNX as of Q2 2018.

Kepos Capital reported no remaining MacroGenics position as of Q2 2018 after selling out during the quarter.
Kepos Capital sold 12,814 MacroGenics shares in Q2 2018, an estimated $322K.
Kepos Capital first reported a position in MacroGenics in Q1 2018 and held it in 1 quarter.
Kepos Capital's MacroGenics position peaked at $322K in Q1 2018.
127 funds tracked by Wall St. Rank held MacroGenics as of Q2 2018.

Based on Kepos Capital's 13F filing for Q2 2018, filed 13 Aug 2018.